Globus Medical, Inc. Class A Common Stock (GMED)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — Aug 11, 2026Investment Snapshot
- Trading 31% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- ROE of 12.5% — below-average profitability
- Revenue growing at 17% annually
Globus Medical, Inc. Class A Common Stock (GMED) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NYSE , with a market capitalisation of $10.5 billion . Key value metrics: P/E ratio 17.5, P/B ratio 2.20, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Globus Medical, Inc. Class A Common Stock — Fundamental Analysis Summary
Globus Medical, Inc. Class A Common Stock (GMED) is currently trading 31% above its Graham Number of $59.64, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 17.5x.
On financial health, GMED shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and modest return on equity of 12.5% (sector average: -20.1%), and minimal leverage with a debt-to-equity ratio of 0.16.
StockPik's composite Value Score for GMED is 91/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
GMED reports a high gross margin of 68.1% (sector average: 37.4%) and a solid operating margin of 17.8%.
GMED shows revenue growing at 17% year-over-year, with earnings growing at 422%.